SLC5A2 and Hypoglycemia: As described above, the risk of hypoglycemia with SGLT-2 inhibitors in non-diabetic patients is likely low as the degree of glucose-lowering positively correlates with the filtered glucose load which is low in non-diabetic CKD populations.